| Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis J Larkins-Ford, T Greenstein, N Van, YN Degefu, MC Olson, A Sokolov, ... Cell systems 12 (11), 1046-1063. e7, 2021 | 41 | 2021 |
| Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements J Larkins-Ford, YN Degefu, N Van, A Sokolov, BB Aldridge Cell Reports Medicine 3 (9), 2022 | 26 | 2022 |
| Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits O Egbelowo, JP Sarathy, K Gausi, MD Zimmerman, H Wang, GJ Wijnant, ... Antimicrobial agents and chemotherapy 65 (9), 10.1128/aac. 00024-21, 2021 | 15 | 2021 |
| Efficient measurement of drug interactions with DiaMOND (diagonal measurement of N-way drug interactions) N Van, YN Degefu, BB Aldridge Mycobacteria Protocols, 703-713, 2021 | 8 | 2021 |
| C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus L Paulowski, KSH Beckham, MD Johansen, L Berneking, N Van, ... PNAS nexus, 2022 | 7 | 2022 |
| Novel Synergies and Isolate Specificities in the Drug Interaction Landscape of Mycobacterium abscessus N Van, YN Degefu, PA Leus, J Larkins-Ford, J Klickstein, FP Maurer, ... Antimicrobial Agents and Chemotherapy 67 (7), e00090-23, 2023 | 2 | 2023 |
